SOLY - Soliton initiates second animal study for potential liver fibrosis treatment

Soliton (SOLY) announces that the company initiated a second pre-clinical study in animals for its Rapid Acoustic Pulse ((RAP)) therapy device as a potential treatment of liver fibrosis.The decision for an additional pre-clinical study follows the first animal study that showed positive results for the potential treatment of the disease.In the initial study, validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse ((RAP)) therapy reduced the effects of induced liver fibrosis 7-days following completion of carbon tetrachloride ((CCL4)) induction by 42%. The RAP device is currently cleared by the FDA for short-term improvement in the appearance of cellulite, and is not yet cleared for the treatment of liver fibrosis.

For further details see:

Soliton initiates second animal study for potential liver fibrosis treatment